Researchers compared data from two pharmaceutical trials in which fidaxomicin, an antibiotic was compared with vancomycin for C. diff treatment.
They subsequently identified four classes of risk factor for the predictive model, including age, number of unformed bowel movements during the previous 24 hours, baseline serum creatinine levels, prior episodes of C. diff and treatment method.
Researchers suggest the model may be useful for clinicians in deciding upon the most effective treatment to prevent recurrence of C. diff infections, something between 20 and 30 percent of those with C. diff experience.
More Articles on Quality:
How a No-Nonsense Hospital CEO Reached the Target of Zero Infections
7 Stories, Studies on Antbiotics
Socioeconomic Status Correlates With Cancer Mortality Rates
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
